Medivation Inc. will pay just $5 million up front, with the potential for another $85 million in development-based milestones and $245 million in sales milestones, for a stake in the PD-1 game through an exclusive global license to Curetech Ltd.'s late-stage molecule, pidilizumab (CT-011).